Organic Active Ingredients TRIZ Cases

A stepped daily telmisartan dose helps control canine hypertension over time, including refractory cases with incomplete response.

Cationic liposomes protect JFK-targeting siRNA from degradation and improve tumor radiosensitivity through nanoparticle delivery.

Small activating RNA targets the HMBS promoter to raise gene expression and enzyme activity, offering faster porphyria treatment with fewer risks.

Controlled oral dosing of a PI3Kδ hemifumarate inhibitor reduces liver, gastrointestinal, and blood toxicities while supporting longer treatment.

A dual-network hydrogel combines covalent and ionic crosslinking to improve toughness, drug stability, and sustained local release.

Functionalized Tymovirus VLPs improve stability, cancer targeting, and intracellular delivery of imaging or therapeutic cargo with reduced toxicity.

Sustained-release polymer drug particles on balloon coatings target lumen strictures to reduce recurrence and repeated interventions.

Combining a PLK1 inhibitor with anti-angiogenic therapy helps inhibit metastatic cancer progression and improve response and survival outcomes.

Substituted salicylamide compounds improve PAD4 inhibition by tuning molecular substituents, helping treat cancer and autoimmune disorders.

A PEG-propylene glycol naproxen fill raises soft gel drug loading without corrosive pH adjustment, enabling smaller capsules and simpler manufacturing.

Targeted carboxylation of psilocybin alters 5-HT2A and 5-HT1A receptor activity to reduce adverse effects while preserving therapeutic efficacy.

Chemically modified hyaluronan forms cross-linked hydrogels that resist rapid clearance and extend use in therapy, cell delivery, and 3D culture.

A CSF-1R inhibitor suppresses M2 macrophages to remodel the tumor microenvironment and boost checkpoint drug efficacy with lower toxicity.

An oil-based sapropterin suspension blocks oxygen exposure, stays homogeneous, and enables easier pediatric dosing without mixing or rinsing.

By stabilizing Nrf2 in glial cells, a DYRK1A inhibitor suppresses neuroinflammation and improves transplanted neuron survival.

Targeted amino acid substitutions shift TNF binding toward TNFR1 over TNFR2, preserving tumor vasculature permeabilization while reducing side effects.

CDR mutations tune EGFR antibody affinity to preserve tumor-cell potency while reducing normal-tissue toxicity in ADC therapy.

Selective CAR peptide targeting concentrates hydrocortisone at injured endothelium to reduce off-target effects and improve survival.

A stepwise pyrazolo[1,5-a]pyrimidine synthesis route improves large-scale TRK inhibitor production through controlled coupling and intermediate formation.

Novel small molecules selectively inhibit MAP4K1 to enhance immune response and support treatment of cancer and viral infection.

Novel camptothecin ADC compounds use tailored linkers and substituents to improve tumor targeting, stability, efficacy, and safety.

A preservative-free oxymetazoline ophthalmic formulation stabilizes long-term storage while lifting eyelids to treat ptosis without surgery.

Separate pH-buffered semaglutide and cagrilintide chambers prevent particle formation during injection while enabling stable combined delivery.

A tailored heterologous UGT boosts conversion of 4-hydroxybenzyl alcohol to gastrodin, reducing multi-enzyme complexity and improving yield.

Formula (1) lipid compounds raise nucleic acid encapsulation and delivery efficiency, offering a non-viral route beyond gene size and immunogenicity limits.

Formula I compounds selectively inhibit CDK8 and CDK19 to modulate gene expression and expand therapeutic options for cancer.

Engineered immune cells combine tumor antigen targeting with prodrug-converting enzymes to boost local cancer killing while limiting toxicity.

Crystalline menin inhibitor forms disrupt the menin-MLL interaction, lowering oncogene expression and promoting cell differentiation in leukemia.

Protein-induced crystallization uses human serum albumin to control aripiprazole crystal form and habit while avoiding harmful solvents.

Exon 68-targeted antisense oligonucleotides bypass USH2A vector size limits by modulating splicing to restore usherin expression.

Substituent-tuned quinazolines improve kinase inhibition while balancing selectivity for EGFR-mutant and other cancer targets.

Treprostinil treatment for interstitial lung disease helps slow pulmonary function decline and improve forced vital capacity.

Crystalline acid salts of an FGFR inhibitor improve handling, storage stability, dissolution, and bioavailability for cancer drug formulation.

Controlled nanofiltration separates HPBCD isomers by substitution range, enabling more selective cholesterol chelation and delivery than crude mixtures.

Combining a PLK1 inhibitor with anti-angiogenic therapy helps slow metastatic cancer progression and improve response outcomes.

A cell-free primase-polymerase process produces high-fidelity closed linear DNA for safer gene delivery and scalable therapeutic manufacturing.

Specific dsRNA motifs with phosphorothioate and 2′-deoxy modifications improve RNAi gene silencing for therapeutic use.

A direct single enteric coating stabilizes omeprazole in acid without an intermediate layer, reducing residual volatile excipients.

Triplet-triplet annihilation lets photosensitizers use far-red light for high-yield photolysis with deeper tissue penetration and lower phototoxicity.

Tumor-targeting NIR dye conjugates deliver therapeutic or diagnostic agents to cancer cells while reducing toxicity to healthy tissue.

An rAAV-delivered anti-VEGF polypeptide plus RNA interference sustains ocular anti-angiogenic activity while reducing injection burden.

Non-viral mobile genetic elements enable stable integration of large transgenes into immune cells while avoiding viral safety and immunogenicity issues.

An amorphous suvorexant-polymer dispersion improves solubility and bioavailability while maintaining practical formulation stability.

Controlled Ullmann and Buchwald coupling replaces microbial culturing to make high-purity farnesyl dibenzodiazepinones faster and at lower cost.

A membrane-separated metformin core and sitagliptin outer layer balance rapid onset with sustained release to improve glycemic control.

pH-sensitive enteric coatings and dispersion matrices protect rapamycin from gastric degradation and improve oral uptake in dogs and cats.

A pH 3-5.5 peptide amide formulation uses minimal excipients to improve stability, low-dose injection safety, and manufacturability.

Targeted cyclopenta[c]pyrrole derivatives inhibit ABHD6 to support treatment of inflammatory and neurological disorders with reduced central side effects.

Selective binding to the TYK2 JH2 pseudokinase domain reduces JAK2 off-target effects while preserving treatment efficacy in autoimmune disease.

N-acylhydrazones compete for physiological metal ions to curb protein oligomerization and oxidative stress in degenerative aggregopathies.